Laser is not a standard treatment
Lentigo maligna is melanoma in situ, not simply a sun spot to remove for cosmetic reasons. Surgery remains the reference treatment; alternatives require specialist assessment when surgery is impractical. Laser should not be offered as equivalent to excision or as a general treatment for melanoma.
The previous version of this page described laser as increasingly established and apparently superior to radiotherapy. That conclusion is not supported by the small retrospective comparison cited. We retain the discussion while distinguishing exploratory findings from reliable clinical indications.
Destroying or lightening pigment can make a lesion less visible without demonstrating that all tumour cells have been eliminated. Choosing a destructive procedure before an adequate diagnosis may also remove tissue needed for histological examination.
Sources for this section: American Academy of Dermatology — Melanoma clinical guideline; Cancer Council Australia — Archived melanoma guideline (2020), lentigo maligna.
The CO₂ laser study: numbers and limitations
Lee and colleagues’ 2011 paper retrospectively examined patients treated between 1991 and 2010. Among the 73 who received treatment, 27 underwent surgery, 31 radiotherapy and only 15 CO₂ laser ablation. One recurrence occurred in the laser group, or 1/15 (6.7%), compared with 9/31 (29%) in the radiotherapy group.
These percentages do not demonstrate that laser reduces recurrence compared with radiotherapy. Allocation was not randomised, groups were small and could differ in lesion characteristics, treatment selection and observation time. A single recurrence in a group of 15 people produces a highly unstable percentage.
The study can generate hypotheses but does not establish therapeutic superiority or a success rate applicable to an individual reader. Its findings cannot be transferred to invasive melanoma or other laser types. Historical studies should be read alongside clinical recommendations rather than turned into a personal promise.
Sources for this section: Lee et al. — Carbon dioxide laser treatment: retrospective comparison (2011).
CO₂, ruby, argon and alexandrite lasers
CO₂ laser is ablative: it removes or destroys tissue through thermal energy. This mechanism is not equivalent to excision with microscopically assessed margins. Treatment depth and the absence of a complete surgical specimen matter when treating a tumour.
Ruby, argon and alexandrite are names found in historical literature on pigmented lesions. Their physical properties differ, but interaction with pigment does not imply selective recognition of malignant cells. They should not be described as devices that eliminate only melanoma while automatically sparing all healthy tissue.
Lentigo maligna may extend beyond visible pigmentation and along skin appendages. A good photographic result does not replace evidence of tumour control. This page therefore provides no ranking of lasers, treatment settings or self-treatment instructions: the issue is oncological care, not simply selecting a cosmetic device.
Sources for this section: Cancer Council Australia — Archived melanoma guideline (2020), lentigo maligna; American Academy of Dermatology — Melanoma clinical guideline; Failure of Q-switched ruby laser to eradicate atypical-appearing solar lentigo: two cases (1998).
Which alternatives to discuss
The first discussion concerns whether appropriate surgery is possible, including techniques that assess margins comprehensively at difficult sites. If surgery is impractical, the team may consider radiotherapy or imiquimod for selected cases of in-situ lentigo maligna. The evidence and limitations of these options are described on the radiotherapy page.
Not every alternative suits the same person, and avoiding a surgical scar is not the only consideration. Diagnostic certainty, possible invasion, extent, general health and ability to attend follow-up all matter. Before accepting a proposal, ask how response will be checked and what will happen if disease remains.
If a previously laser-treated area becomes pigmented again, changes or develops a nodule, it needs dermatological assessment. Bring photographs and records of the previous procedure if available; do not repeat cosmetic treatment simply to make the mark disappear.
Sources for this section: American Academy of Dermatology — Melanoma clinical guideline; NICE NG14 — Melanoma: assessment and management, recommendations.
Research: what safeguards to ask about
Calling a procedure “innovative” does not establish efficacy. Any experimental use of laser should have an identifiable protocol, clear clinical responsibility, ethical review and informed consent. Patients need to know how absence of invasion, response, recurrence and adverse effects will be documented, and which alternatives are offered.
Taking part in a study does not guarantee personal benefit. Experimental approaches do not all have the same evidence level, and abandoning indicated treatment merely because another approach is described as less invasive is not justified. For an overview of current melanoma research, see the experimental-treatment section on the parent page.
The Australian 2020 recommendations cited below are explicitly an archived document: they provide context for laser treatment and are not presented as a 2026 update. Current decisions require discussion with the specialist centre and clinical sources relevant to the individual case.
Sources for this section: National Cancer Institute — Participate in Cancer Treatment Trials; Cancer Council Australia — Archived melanoma guideline (2020), lentigo maligna.
Sources and update
- American Academy of Dermatology — Melanoma clinical guideline
- Cancer Council Australia — Archived melanoma guideline (2020), lentigo maligna
- Lee et al. — Carbon dioxide laser treatment: retrospective comparison (2011)
- Failure of Q-switched ruby laser to eradicate atypical-appearing solar lentigo: two cases (1998)
- NICE NG14 — Melanoma: assessment and management, recommendations
- National Cancer Institute — Participate in Cancer Treatment Trials
Editorial revision and source consultation: 17 October 2026. Study dates distinguish current evidence from historical documents. This date does not certify specialist clinical review.